Systematic Review and Meta-Analysis of the Impact of Computed Tomography–Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation

American Journal of Transplantation

Volumn 16, Issue 8, 2016, Pages 2277-2292

  van Vugt, J L A ^a   Levolger, S ^a   de Bruin, R W F ^a   van Rosmalen, J ^a   Metselaar, H J ^a   IJzermans, J N M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

classification systems; clinical research practice; comorbidities; complication; complication: infectious; diagnostic techniques and imaging: computed tomography; health services and outcomes research; liver transplantation hepatology

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIVER GRAFT; LIVER TRANSPLANTATION; META ANALYSIS; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MUSCLE MASS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PSOAS MUSCLE; REVIEW; SARCOPENIA; SKELETAL MUSCLE; SYSTEMATIC REVIEW;

EID: 84978904260     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13732     Document Type: Review

References (45)

1. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851–858.
2. Brown RS, Rush SH, Rosen HR, et al. Liver and intestine transplantation. Am J Transplant 2004; 4(Suppl 9): 81–92.
3. Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS ONE 2013; 8: e51926.
4. Myers RP, Tandon P, Ney M, et al. Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int 2014; 34: 1176–1183.
5. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14: 1870–1879.
6. Levolger S, van Vugt JL, de Bruin RW, IJzermans JN. Systematic review of sarcopenia in patients operated forresectable gastrointestinal and hepatopancreatobiliary malignancies. Br J Surg 2015; 102: 1448–1458.
7. Reisinger KW, van Vugt JL, Tegels JJ, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg 2015; 261: 345–352.
8. van Vugt JL, Braam HJ, van Oudheusden TR, et al. Skeletal muscle depletion is associated with severe postoperative complications in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2015; 22: 3625–3631.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 2010; 8: 336–341.
10. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014 [cited 2015 May 20]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
12. Bergerson JT, Lee JG, Furlan A, et al. Liver transplantation arrests and reverses muscle wasting. Clin Transplant 2015; 29: 216–221.
13. Cruz RJ Jr, Dew MA, Myaskovsky L, et al. Objective radiologic assessment of body composition in patients with end-stage liver disease: Going beyond the BMI. Transplantation 2013; 95: 617–622.
14. DiMartini A, Cruz RJ Jr, Dew MA, et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl 2013; 19: 1172–1180.
15. Durand F, Buyse S, Francoz C, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60: 1151–1157.
16. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271–278.
17. Giusto M, Lattanzi B, Albanese C, et al. Sarcopenia in liver cirrhosis: The role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol 2015; 3: 328–334.
18. Hamaguchi Y, Kaido T, Okumura S, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl 2014; 20: 1413–1419.
19. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19: 1396–1402.
20. Lee CS, Cron DC, Terjimanian MN, et al. Dorsal muscle group area and surgical outcomes in liver transplantation. Clin Transplant 2014; 28: 1092–1098.
21. Masuda T, Shirabe K, Ikegami T, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl 2014; 20: 401–407.
22. Meza-Junco J, Montano-Loza AJ, Baracos VE, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 2013; 47: 861–870.
23. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166–173, 173.e1.
24. Montano-Loza AJ, Meza-Junco J, Baracos VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20: 640–648.
25. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value. Liver Transpl 2012; 18: 1209–1216.
26. Toshima T, Shirabe K, Kurihara T, et al. Profile of plasma amino acids values as a predictor of sepsis in patients following living donor liver transplantation: Special reference to sarcopenia and postoperative early nutrition. Hepatol Res 2015; 45: 1170–1177.
27. Tsien C, Garber A, Narayanan A, et al. Post-liver transplantation sarcopenia in cirrhosis: A prospective evaluation. J Gastroenterol Hepatol 2014; 29: 1250–1257.
28. Valero V 3rd, Amini N, Spolverato G, et al. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg 2015; 19: 272–281.
29. Waits SA, Kim EK, Terjimanian MN, et al. Morphometric age and mortality after liver transplant. JAMA Surg 2014; 149: 335–340.
30. Yadav A, Chang YH, Carpenter S, et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant 2015; 29: 134–141.
31. Carey EJ. Sarcopenia in solid organ transplantation. Nutr Clin Pract 2014; 29: 159–170.
32. Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647.
33. Montano-Loza AJ. Muscle wasting: A nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr Metab Care 2014; 17: 219–225.
34. Kamath PS, Kim WR; Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797–805.
35. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008; 9: 629–635.
36. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539–1547.
37. Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (MENAC). 2015 [cited 2015 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926.
38. Dingemans AM, de Vos-Geelen J, Langen R, Schols AM. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs 2014; 23: 1655–1669.
39. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018–1026.
40. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol 2015; 6: e102.
41. Merli M, Giusto M, Gentili F, et al. Nutritional status: Its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010; 30: 208–214.
42. Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Muller MJ. Identification of high- and low-risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997; 25: 652–657.
43. Stephenson GR, Moretti EW, El-Moalem H, Clavien PA, Tuttle-Newhall JE. Malnutrition in liver transplant patients: Preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001; 72: 666–670.
44. Englesbe MJ. Quantifying the eyeball test: Sarcopenia, analytic morphomics, and liver transplantation. Liver Transpl 2012; 18: 1136–1137.
45. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011; 12: 489–495.